XENE
insider transactionsXenon Pharmaceuticals Inc. — buys & sells by directors, officers and 10% owners A shareholder owning more than 10% of the company. Must report trades, but usually a weaker signal than an officer or director. (SEC Form 4).
Net shares · 365d
-387.0K
0 buy · 387.0K sell
Net value · 365d
-$21.8M
$0 in · $21.8M out
Sentiment · 365d
Net selling
0% buying · 100% selling
Open-market trades · 365d
22
0 buy · 387.0K sell
Net buy / sell volume
Not enough data to chart yet.
Tap or hover the chart for daily net volume. Green = net buying, red = net selling.
All transactions
-
Sell·S
Chief Medical Officer · 10b5-1
$77.9K
1.4K sh · $55.23
Own -17%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$403.6K
7.3K sh · $55.23
Own -27%
-
Sell·S
Chief Legal Officer · 10b5-1
$74.1K
1.3K sh · $55.23
Own -16%
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
3.8K sh
Own +50%
-
Exercise·M
Chief Medical Officer · 10b5-1
—
3.8K sh
Own +79%
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$0
12.5K sh
Own +50%
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
—
12.5K sh
Own +85%
-
Exercise·M
Chief Legal Officer · 10b5-1
$0
3.8K sh
Own +50%
-
Exercise·M
Chief Legal Officer · 10b5-1
—
3.8K sh
Own +77%
-
Sell·S
Chief Medical Officer · 10b5-1
$166.6K
2.8K sh · $60.11
Own -37%
-
Sell·S
Chief Legal Officer · 10b5-1
$156.7K
2.6K sh · $60.11
Own -35%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$677.4K
11.3K sh · $60.11
Own -43%
-
Grant·A
Chief Medical Officer · 10b5-1
$0
7.5K sh
Own New
-
Exercise·M
Chief Medical Officer · 10b5-1
$0
7.5K sh
Own New
-
Exercise·M
Chief Medical Officer · 10b5-1
—
7.5K sh
Own New
-
Grant·A
Chief Legal Officer · 10b5-1
$0
7.5K sh
Own New
-
Exercise·M
Chief Legal Officer · 10b5-1
$0
7.5K sh
Own New
-
Exercise·M
Chief Legal Officer · 10b5-1
—
7.5K sh
Own New
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$0
25.0K sh
Own New
-
Grant·A
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$0
20.0K sh
Own New
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$0
20.0K sh
Own New
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$0
105.0K sh
Own New
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$0
75.0K sh
Own New
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$0
65.0K sh
Own New
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
—
20.0K sh
Own +333%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$4.0M
65.0K sh · $62.06
Own -92%
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$613.6K
65.0K sh · $9.44
Own +1083%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$3.7M
61.7K sh · $60.08
Own -91%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$2.6M
43.3K sh · $59.26
Own -37%
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$498.8K
105.0K sh · $4.75
Own +1750%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$150.0K
2.4K sh · $61.26
Own -29%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$609.1K
10.1K sh · $60.47
Own -54%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$742.5K
12.5K sh · $59.50
Own -40%
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$77.5K
25.0K sh · $3.10
Own +417%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$1.3M
21.5K sh · $60.49
Own -78%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$1.9M
31.7K sh · $59.88
Own -54%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$1.3M
21.8K sh · $58.81
Own -27%
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$630.0K
75.0K sh · $8.40
Own +1250%
-
Grant·A
Chief Commercial Officer
$0
40.0K sh
Own New
-
Grant·A
Chief Commercial Officer
$0
20.0K sh
Own New
-
Grant·A
MORTIMER IAN KEY
PRESIDENT & CEO
$0
350.0K sh
Own New
-
Grant·A
MORTIMER IAN KEY
PRESIDENT & CEO
$0
65.0K sh
Own New
-
Grant·A
Chief Legal Officer
$0
80.0K sh
Own New
-
Grant·A
Chief Legal Officer
$0
15.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
100.0K sh
Own New
-
Grant·A
Chief Medical Officer
$0
20.0K sh
Own New
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$0
40.0K sh
Own New
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$92.6K
2.1K sh · $44.93
Own -26%
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$299.6K
40.0K sh · $7.49
Own +667%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$1.7M
37.9K sh · $44.40
Own -82%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$402.1K
8.8K sh · $45.59
Own -52%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$93.1K
2.0K sh · $46.32
Own -25%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$647.3K
14.4K sh · $45.03
Own -46%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT & CEO · 10b5-1
$4.4K
97 sh · $45.01
Own -0%
-
Grant·A
Chief Financial Officer
$0
30.0K sh
Own New
-
Grant·A
Chief Financial Officer
$0
225.0K sh
Own New
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT, CEO & INTERIM CFO · 10b5-1
$0
25.0K sh
Own New
-
Exercise·M
MORTIMER IAN KEY
PRESIDENT, CEO & INTERIM CFO · 10b5-1
$192.2K
25.0K sh · $7.69
Own +80%
-
Sell·S
MORTIMER IAN KEY
PRESIDENT, CEO & INTERIM CFO · 10b5-1
$1.0M
25.0K sh · $40.16
Own -44%
-
Grant·A
Chief Commercial Officer
$0
185.8K sh
Own New
| Date▾ | Insider | Type | Shares | Value |
|---|---|---|---|---|
| Mar 13, 2026 | KENNEY CHRISTOPHER JOHN 10b5-1 | Sell S | 1.4K | $77.9K |
| Mar 13, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 7.3K | $403.6K |
| Mar 13, 2026 | DiFabio Andrea 10b5-1 | Sell S | 1.3K | $74.1K |
| Mar 12, 2026 | KENNEY CHRISTOPHER JOHN 10b5-1 | Exercise M | 3.8K | $0 |
| Mar 12, 2026 | KENNEY CHRISTOPHER JOHN 10b5-1 | Exercise M | 3.8K | — |
| Mar 12, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 12.5K | $0 |
| Mar 12, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 12.5K | — |
| Mar 12, 2026 | DiFabio Andrea 10b5-1 | Exercise M | 3.8K | $0 |
| Mar 12, 2026 | DiFabio Andrea 10b5-1 | Exercise M | 3.8K | — |
| Mar 10, 2026 | KENNEY CHRISTOPHER JOHN 10b5-1 | Sell S | 2.8K | $166.6K |
| Mar 10, 2026 | DiFabio Andrea 10b5-1 | Sell S | 2.6K | $156.7K |
| Mar 10, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 11.3K | $677.4K |
| Mar 9, 2026 | KENNEY CHRISTOPHER JOHN 10b5-1 | Grant A | 7.5K | $0 |
| Mar 9, 2026 | KENNEY CHRISTOPHER JOHN 10b5-1 | Exercise M | 7.5K | $0 |
| Mar 9, 2026 | KENNEY CHRISTOPHER JOHN 10b5-1 | Exercise M | 7.5K | — |
| Mar 9, 2026 | DiFabio Andrea 10b5-1 | Grant A | 7.5K | $0 |
| Mar 9, 2026 | DiFabio Andrea 10b5-1 | Exercise M | 7.5K | $0 |
| Mar 9, 2026 | DiFabio Andrea 10b5-1 | Exercise M | 7.5K | — |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 25.0K | $0 |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Grant A | 20.0K | $0 |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 20.0K | $0 |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 105.0K | $0 |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 75.0K | $0 |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 65.0K | $0 |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 20.0K | — |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 65.0K | $4.0M |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 65.0K | $613.6K |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 61.7K | $3.7M |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 43.3K | $2.6M |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 105.0K | $498.8K |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 2.4K | $150.0K |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 10.1K | $609.1K |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 12.5K | $742.5K |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 25.0K | $77.5K |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 21.5K | $1.3M |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 31.7K | $1.9M |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 21.8K | $1.3M |
| Mar 9, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 75.0K | $630.0K |
| Jan 9, 2026 | Cline Darren S | Grant A | 40.0K | $0 |
| Jan 9, 2026 | Cline Darren S | Grant A | 20.0K | $0 |
| Jan 9, 2026 | MORTIMER IAN KEY | Grant A | 350.0K | $0 |
| Jan 9, 2026 | MORTIMER IAN KEY | Grant A | 65.0K | $0 |
| Jan 9, 2026 | DiFabio Andrea | Grant A | 80.0K | $0 |
| Jan 9, 2026 | DiFabio Andrea | Grant A | 15.0K | $0 |
| Jan 9, 2026 | KENNEY CHRISTOPHER JOHN | Grant A | 100.0K | $0 |
| Jan 9, 2026 | KENNEY CHRISTOPHER JOHN | Grant A | 20.0K | $0 |
| Jan 2, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 40.0K | $0 |
| Jan 2, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 2.1K | $92.6K |
| Jan 2, 2026 | MORTIMER IAN KEY 10b5-1 | Exercise M | 40.0K | $299.6K |
| Jan 2, 2026 | MORTIMER IAN KEY 10b5-1 | Sell S | 37.9K | $1.7M |
| Dec 8, 2025 | MORTIMER IAN KEY 10b5-1 | Sell S | 8.8K | $402.1K |
| Dec 8, 2025 | MORTIMER IAN KEY 10b5-1 | Sell S | 2.0K | $93.1K |
| Dec 5, 2025 | MORTIMER IAN KEY 10b5-1 | Sell S | 14.4K | $647.3K |
| Nov 28, 2025 | MORTIMER IAN KEY 10b5-1 | Sell S | 97 | $4.4K |
| Oct 15, 2025 | Kelly Thomas Patrick KEY | Grant A | 30.0K | $0 |
| Oct 15, 2025 | Kelly Thomas Patrick KEY | Grant A | 225.0K | $0 |
| Oct 1, 2025 | MORTIMER IAN KEY 10b5-1 | Exercise M | 25.0K | $0 |
| Oct 1, 2025 | MORTIMER IAN KEY 10b5-1 | Exercise M | 25.0K | $192.2K |
| Oct 1, 2025 | MORTIMER IAN KEY 10b5-1 | Sell S | 25.0K | $1.0M |
| Jun 23, 2025 | Cline Darren S | Grant A | 185.8K | $0 |
About XENE insider trading
This page tracks insider transactions for Xenon Pharmaceuticals Inc. (XENE) reported to the U.S. Securities and Exchange Commission on Form 4. Corporate insiders — directors, executive officers and beneficial owners of more than 10% of the stock — must disclose their trades within two business days. Open-market purchases (code P) and sales (code S) made at the insider's discretion are the most-watched opportunistic signals, while awards (A), option exercises (M) and tax-withholding (F) reflect compensation rather than conviction. Trades marked 10b5-1 were made under a pre-arranged plan and are considered routine. A cluster buy — several insiders buying within a short window — is historically a stronger bullish indicator than any single trade.